Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles
View/ Open
s41589-020-0501-5.pdf (4.775Mb)
Access Status
Full text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.Author
Eaton, John K.
Furst, Laura
Moosmayer, Dieter
Hilpmann, André
Ryan, Matthew J.
Zimmermann, Katja
Cai, Luke L.
Niehues, Michael
Badock, Volker
Kramm, Anneke
Hillig, Roman C.
Gradl, Stefan
Montagnon, Claire
Lazarski, Kiel E.
Christian, Sven
Neuhaus, Roland
Eheim, Ashley L.
Viswanathan, Vasanthi S
Schreiber, Stuart L
Published Version
https://doi.org/10.1038/s41589-020-0501-5Metadata
Show full item recordCitation
Eaton, John K., Laura Furst, Richard Ruberto, Dieter Moosmayer, André Hilpmann, Matthew J. Ryan, Katja Zimmermann et al. "Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles." Nat Chem Biol 16, no. 5 (2020): 497-506. DOI: 10.1038/s41589-020-0501-5Abstract
We recently described glutathione peroxidase 4 (GPX4) as a promising target for killing therapy-resistant cancer cells via ferroptosis. The onset of therapy resistance by multiple types of treatment results in a stable cell state marked by high levels of polyunsaturated lipids and an acquired dependency on GPX4. Unfortunately, all existing inhibitors of GPX4 act covalently via a reactive alkyl chloride moiety that confers poor selectivity and pharmacokinetic properties. Here, we report our discovery that masked nitrile-oxide electrophiles, which have not been explored previously as covalent cellular probes, undergo remarkable chemical transformations in cells and provide an effective strategy for selective targeting of GPX4. The new GPX4-inhibiting compounds we describe exhibit unexpected proteome-wide selectivity and, in some instances, vastly improved physiochemical and pharmacokinetic properties compared to existing chloroacetamide-based GPX4 inhibitors. These features make them superior tool compounds for biological interrogation of ferroptosis and constitute starting points for development of improved inhibitors of GPX4.Citable link to this page
https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37374459
Collections
- FAS Scholarly Articles [18153]
Contact administrator regarding this item (to report mistakes or request changes)